MGMT and ovarian carcinoma: The pooled OR showed that the methylation of the MGMT promoter was not correlated with clinical stage (OR = 1.46, 95% CI = 0.71–3.02, p = .301), including 223 patients with stage 3–4 and 69 patients with stage 1–2 ovarian carcinoma among four studies.